Michigan City, FL, United States
Michigan City, FL, United States

Time filter

Source Type

News Article | October 28, 2016
Site: www.marketwired.com

MIAMI, FL--(Marketwired - October 28, 2016) - Dr. Sergio Gonzalez-Arias, chief of neurological surgery at Baptist Hospital and chair of the Department of Neuroscience at FIU's Herbert Wertheim College of Medicine, will join the College of Medicine's executive team as executive associate dean for clinical affairs. Gonzalez-Arias, who will begin his new position with the Herbert Wertheim College of Medicine in January 2017, will oversee all clinical functions at the College of Medicine, including the students' clinical experience; all strategic partnerships with hospitals and other clinical sites where students perform their clinical rotations; and development of Graduate Medical Education. "We have been fortunate to work with Dr. Gonzalez-Arias as a key member of our faculty since 2010. Now he brings to his new position a wealth of clinical experience that will add to the development of clinical programs to the College of Medicine," said Dr. John A. Rock, founding dean of the Herbert Wertheim College of Medicine and FIU senior vice president for health affairs. Wayne Brackin, executive vice president and chief operating officer for Baptist Health South Florida, said Gonzalez-Arias has made important contributions to the field of neuroscience. "Dr. Gonzalez-Arias is a well-respected neurosurgeon who has advanced his profession and expanded the comprehensive neuroscience offerings at Baptist Health," Brackin said. "As the founding medical director of Baptist Health Neuroscience Center he has developed and implemented surgical and technological advancements that have had a profound impact on our patients." Gonzalez-Arias is the founding and current medical director of Baptist Health Neuroscience Center. He has served as chief of Baptist Hospital's Department of Surgery and is a past president of the medical staff. He is a fellow of the American Association of Neurological Surgeons and the American College of Surgeons. He served as chair of the international committee of the Joint Council of State Neurosurgical Societies and is a past president of the Florida Neurological Society. "I am excited about this new opportunity at the FIU College of Medicine, which will allow me to continue building on its impressive growth, which I am honored to have been part of for several years," Gonzalez-Arias said. "In keeping with the best practice of a multidisciplinary approach to medicine, I look forward to collaborating with the university's hospital and community partners to research, innovate and continue making a significant positive impact on medical education and healthcare in our community." Dr. Gonzalez-Arias is a graduate of the University of Zaragoza (Spain) and completed his residencies at Rush-Presbyterian St. Luke's Medical Center and the University of Miami/Jackson Memorial Hospital. About Baptist Health South Florida: Baptist Health South Florida is the largest healthcare organization in the region, with seven hospitals (Baptist Hospital, Baptist Children's Hospital, Doctors Hospital, Homestead Hospital, Mariners Hospital, South Miami Hospital and West Kendall Baptist Hospital), nearly 50 outpatient and urgent care facilities, Baptist Health Medical Group, Baptist Health Quality Network and internationally renowned centers of excellence. The not-for-profit, faith-based Baptist Health has approximately 16,000 employees and 2,300 affiliated physicians. Baptist Health South Florida has been recognized as one of the 100 Best Companies to Work For in America and as one of the World's Most Ethical Companies. For more information, visit BaptistHealth.net and connect with us on Facebook at facebook.com/BaptistHealthSF and on Twitter and Instagram @BaptistHealthSF. About The FIU Herbert Wertheim College of Medicine: The Herbert Wertheim College of Medicine was approved in 2006 by the Florida Board of Governors and the Florida Legislature, and in February 2013 the medical degree program received full accreditation from the Liaison Committee for Medical Education. The College graduated its inaugural class on April 29, 2013. Among the innovative elements of the HWCOM is a program called Green Family Foundation NeighborhoodHELP™ that sends teams of medical students along with their counterparts in social work, nursing, and law into the community. The College of Medicine's mission is to lead the next generation of medical education and improve the quality of health care available to the South Florida community. For more information visit http://medicine.fiu.edu/ About FIU: Florida International University is classified by Carnegie as a "R1: Doctoral Universities - Highest Research Activity" and recognized as a Carnegie Community Engaged university. It is a public research university with colleges and schools that offers bachelor's, master's and doctoral programs in fields such as business engineering, computer science, international relations, architecture, law and medicine. As one of South Florida's anchor institutions, FIU contributes almost $9 billion each year to the local economy and is ranked second in Florida in Forbes Magazine's "America's Best Employers" list. FIU graduates are consistently among the highest paid college graduates in Florida and are among the leaders of public and private organizations throughout South Florida. FIU is Worlds Ahead in finding solutions to the most challenging problems of our time. FIU emphasizes research as a major component of its mission with multiple state-of-the-art research facilities including the Wall of Wind Research and Testing Facility, FIU's Medina Aquarius Program and the Advanced Materials Engineering Research Institute. FIU has awarded more than 220,000 degrees and enrolls more than 54,000 students in two campuses and centers including FIU Downtown on Brickell, FIU@I-75, the Miami Beach Urban Studios, and Tianjin, China. FIU also supports artistic and cultural engagement through its three museums: Patricia & Phillip Frost Art Museum, the Wolfsonian-FIU, and the Jewish Museum of Florida-FIU. FIU is a member of Conference USA and more than 400 student-athletes participating in 18 sports. For more information about FIU, visit http://www.fiu.edu/.


News Article | December 8, 2016
Site: www.prnewswire.co.uk

European and U.S. Hospitals Advance Adaptive Cancer Care with Image-Guided Radiation Therapy System Accuray Incorporated (NASDAQ: ARAY) announced today that leading hospitals in Europe and the United States are now treating patients with the new Radixact™ Treatment Delivery System, fully integrated with the new Accuray Precision™ Treatment Planning System and iDMS™ Data Management System. The first patient treatment in the world was administered at the University Hospital Brussels (UZ Brussel) in Belgium and in the United States at Froedtert & the Medical College of Wisconsin Froedtert Hospital in Milwaukee, Wisconsin, part of the Froedtert & MCW Cancer Network. The University Hospital Brussels (UZ Brussel) continues its legacy of innovation with the installation of the Radixact System, software, and treatment of the first patient worldwide. The smart new radiation therapy system represents the next generation in TomoTherapy® treatment delivery, significantly increasing treatment speed and ease of use. It enables clinicians to treat a wide range of cancer cases, from routine to complex, with precision and increased efficiency. "We are proud and excited to be the first hospital in the world to offer the new Radixact treatment option to our patients here in Brussels. This advanced technology represents another step forward toward optimal cancer care and improved quality of life for patients," said Prof. Mark De Ridder, Head of the Radiation Oncology Department, University Hospital Brussels (UZ Brussel, Vrije Universiteit Brussel). "The first patient who underwent a Radixact procedure received radiation to treat a metastatic mass in the neck. We are now actively treating patients across a broad range of cases and all treatments have gone smoothly. The precision software is straightforward, the image quality on the system is improved and dose delivery is efficient." Additionally, patients in France will have access to the Radixact System with its recent installation at the IUCT Oncopole - Institut Universitaire du Cancer de Toulouse in Toulouse, France. The hospital's clinical experts use the most current advances in cancer treatments to develop personalized programs which improve the quality of care they provide to patients. The Radixact System in the United States Multiple sites in the United States are now equipped with the Radixact System. Miami Cancer Institute, a part of Baptist Health South Florida, and Froedtert & MCW Cancer Network are the first to install the system. Froedtert Hospital treated the first patient in the United States and is the only cancer program in the Midwest currently offering treatment with the advanced Radixact platform. Froedtert and MCW physicians selected this system because it expands cancer treatment capabilities to improve patients' outcomes and quality of life. "For more than a decade, the Froedtert & MCW Cancer Network has been at the forefront of the evolution of image-guided and adaptive radiation therapy with the goal of providing more personalized treatments," said Christopher Schultz, MD, FACR, Medical College of Wisconsin Professor and Chairman of the Department of Radiation Oncology with the Froedtert & MCW Cancer Network. "The new Radixact™ platform tightly integrates the treatment planning function with the delivery of image-guided, highly conformal treatments and importantly, provides the tools to perform plan adaption when necessary." The Radixact System was also chosen as the newest approach in advanced radiation therapy treatment for the new state-of-the-art $430 million facility at Miami Cancer Institute. "Being the first in the Southeast to offer this sophisticated technology helps to further expand the comprehensive radiation treatments available to Miami Cancer Institute's patient population, giving our unique and integrated department the opportunity to deliver therapies best suited to treat a wide variety of cancers," said Minesh P. Mehta, M.D., Deputy Director and Chief of Radiation Oncology at Miami Cancer Institute. The Radixact® System leverages the TomoTherapy® System's efficient, daily low-dose fan beam MVCT image guidance and unique ring gantry architecture to deliver precise radiation treatments for more patients, every day. "We are excited about the early momentum in the adoption of this new radiation therapy platform. Our customers have already treated patients with the Radixact System, demonstrating their confidence in its value as a mainstream treatment option," said Joshua H. Levine, president and chief executive officer of Accuray. "These early adopters are leading the way for other hospitals and clinics seeking an innovative and effective technology to help them provide best-in-class radiation treatments for their cancer patients now and into the future." For further information on the Radixact System, visit http://www.accuray.com . For Important Safety Information please refer to http://www.accuray.com/safety-statement-radiation-treatment Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit http://www.accuray.com. Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, market acceptance of our new technologies, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's report on Form 10-Q, filed on November 1, 2016, and as updated periodically with the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.


With an upcoming publication in the Worldwide Leaders in Healthcare, Alberto J. Fernandez, RN, BSN, joins the prestigious ranks of the International Nurses Association. Alberto J. Fernandez is a Registered Nurse with seven years of experience in his field and an extensive expertise in all facets of nursing, especially Neuro-Stepdown unit and Stroke Rehabilitation nursing. Alberto is currently serving patients within Baptist Health South Florida, a faith based, non profit healthcare organization and clinical care network in Southern Florida. Alberto attended the University of Phoenix, where he graduated with his Bachelor of Science Degree in Nursing in 2014. An advocate for continuing education, he is currently pursuing his Master of Science Degree in Nursing with a Family Practice Nurse concentration at the University of Miami with a projected graduation in 2018. To keep up to date with the latest advances and developments in the challenging nursing field, Alberto maintains a professional membership with the American Nurses Association. Learn more about Alberto J. Fernandez here: http://inanurse.org/network/index.php?do=/4135265/info/ and be sure to read his upcoming publication in the Worldwide Leaders in Healthcare.


News Article | March 2, 2017
Site: www.businesswire.com

MIAMI--(BUSINESS WIRE)--Miami Cardiac & Vascular Institute has completed its $120 million expansion project on the Baptist Hospital campus. The state-of-the-art facility includes additional space and cutting-edge technology, facilitating the creation of several new, specialized programs bringing together multidisciplinary teams of specialists to treat the cardiovascular system as a single entity. The expansion added 60,000 square feet of new space and included 40,000 square feet of renovations, nearly doubling the size of the Institute to 150,000 square feet in order to accommodate a growing number of patients and procedures. Since it was founded in 1987, Institute physicians have pioneered less-invasive techniques to treat aneurysms, stroke and heart disease, and have been part of many groundbreaking research trials. For 30 years, Miami Cardiac & Vascular Institute has been an integral innovation partner for Philips, a world leader in healthcare technologies, providing valuable clinical insights that have led to the development of industry-leading solutions such as the recently announced Philips Azurion Image Guided Therapy (IGT) system. The expansion includes a state-of-the-art Cath lab, representing the first North American installation of Azurion. The system is designed to anticipate what clinicians need, when they need it, to make procedures flow intuitively and support a superior patient experience. “This expansion allows us to be at the forefront of medical innovation and provides the most current treatment options for our patients, while at the same time, prepares us to be in the position to care for health problems we haven’t even encountered yet,” said Barry T. Katzen, M.D., Chief Medical Executive and founder of the Institute. “We are now able to conduct more research, offer new services and make discoveries that could transform how cardiovascular care is delivered.” Throughout its history, the Institute’s physicians have pioneered less-invasive techniques to treat aneurysms, stroke and heart disease, and have been part of many groundbreaking research trials. The newly expanded Institute, with its cutting-edge equipment and unique programs, allows our internationally respected physicians to continue their visionary work. One of the first elements of the three-year project was the expansion of Baptist Hospital’s Surgery Center, which now includes six large operating rooms dedicated to neuroscience, cardiac, vascular and robotic surgery. The Institute also added four new advanced endovascular suites with enlarged gallery viewing areas for enhanced teaching and learning opportunities. “This is the centerpiece of the expansion, the Center for Advanced Endovascular Therapies,” Dr. Katzen explained. “We wanted to create an environment in which we could do any type of predominantly image-guided procedure, where physicians of different disciplines could work together to create unique solutions for patients’ problems.” In designing interventional suites of the future, two of the new endovascular suites have glass walls and a video system that allow people to sit in a theater-style chair outside of the suite and control what they are watching using an iPad. Viewers from different disciplines or in training each can have their own unique user interface that allows them to pick and choose which parts of the procedure they want to watch, all with communication with the suites. Additionally, the Institute makeover created the National Center for Aneurysm Therapy — the first in the world — a Center for Structural Heart Therapy, Center for Critical Limb Ischemia and an Advanced Arrhythmia Therapy Center. It is here where physicians are doing research to discover more cardiovascular disease breakthroughs. “We are proud to open the doors of the new Miami Cardiac & Vascular Institute to our community,” said Brian E. Keeley, President and CEO of Baptist Health South Florida. “This expansion now provides even greater promise to our patients, with new state-of-the-art interventional procedure suites; an expansive, high-tech gallery for observation, diagnostics and greater teaching opportunities; and, research space for more than 120 clinical trials.” Miami Cardiac & Vascular Institute is the largest and most comprehensive cardiovascular facility in the region, consisting of 76 doctors and 1,100 employees system-wide serving 125,000 patients every year. “At Philips, we are committed to building a healthy society by creating solutions that are going to have a meaningful impact in improving human health, and this requires collaboration with pioneering organizations like Miami Cardiac & Vascular Institute,” said Brent Shafer, CEO of Philips North America. “The Institute’s clinical insights have been critical to the development of our Azurion technology, from understanding workflows and improving efficiencies, to understand how to improve the patient experience. Together, we are shaping the future of healthcare by making procedures safer and more efficient. This will not only help address the health issues in South Florida communities, it will allow us to apply those lessons globally to help tackle the challenges of rising healthcare costs and better access to care. Ultimately, we want to improve the patient experience and outcomes, one community at a time.” Miami Cardiac & Vascular Institute is the largest and most comprehensive cardiovascular facility in the region. The team of multilingual, multidisciplinary specialists has pioneered the development of minimally invasive techniques used to treat aneurysms, blockages in veins and arteries and holes in the heart. Miami Cardiac & Vascular Institute is part of Baptist Health South Florida, the largest healthcare organization in the region, with seven hospitals (Baptist Hospital, Baptist Children’s Hospital, Doctors Hospital, Homestead Hospital, Mariners Hospital, South Miami Hospital and West Kendall Baptist Hospital), nearly 50 outpatient and urgent care facilities, Baptist Health Medical Group, Baptist Health Quality Network and internationally renowned centers of excellence. The not-for-profit, faith-based Baptist Health has approximately 16,000 employees and 2,300 affiliated physicians. Baptist Health South Florida has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies. For more information, visit BaptistHealth.net and connect with us on Facebook at facebook.com/BaptistHealthSF and on Twitter and Instagram @BaptistHealthSF. Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.


News Article | March 2, 2017
Site: www.marketwired.com

MIAMI, FL--(Marketwired - March 02, 2017) - Miami Cardiac & Vascular Institute has completed its $120 million expansion project on the Baptist Hospital campus. The state-of-the-art facility includes additional space and cutting-edge technology, facilitating the creation of several new, specialized programs bringing together multidisciplinary teams of specialists to treat the cardiovascular system as a single entity. The expansion added 60,000 square feet of new space and included 40,000 square feet of renovations, nearly doubling the size of the Institute to 150,000 square feet in order to accommodate a growing number of patients and procedures. Since it was founded in 1987, Institute physicians have pioneered less-invasive techniques to treat aneurysms, stroke and heart disease, and have been part of many groundbreaking research trials. For 30 years, Miami Cardiac & Vascular Institute has been an integral innovation partner for Philips, a world leader in healthcare technologies, providing valuable clinical insights that have led to the development of industry-leading solutions such as the recently announced Philips Azurion Image Guided Therapy (IGT) system. The expansion includes a state-of-the-art Cath lab, representing the first North American installation of Azurion. The system is designed to anticipate what clinicians need, when they need it, to make procedures flow intuitively and support a superior patient experience. "This expansion allows us to be at the forefront of medical innovation and provides the most current treatment options for our patients, while at the same time, prepares us to be in the position to care for health problems we haven't even encountered yet," said Barry T. Katzen, M.D., Chief Medical Executive and founder of the Institute. "We are now able to conduct more research, offer new services and make discoveries that could transform how cardiovascular care is delivered." Throughout its history, the Institute's physicians have pioneered less-invasive techniques to treat aneurysms, stroke and heart disease, and have been part of many groundbreaking research trials. The newly expanded Institute, with its cutting-edge equipment and unique programs, allows our internationally respected physicians to continue their visionary work. One of the first elements of the three-year project was the expansion of Baptist Hospital's Surgery Center, which now includes six large operating rooms dedicated to neuroscience, cardiac, vascular and robotic surgery. The Institute also added four new advanced endovascular suites with enlarged gallery viewing areas for enhanced teaching and learning opportunities. "This is the centerpiece of the expansion, the Center for Advanced Endovascular Therapies," Dr. Katzen explained. "We wanted to create an environment in which we could do any type of predominantly image-guided procedure, where physicians of different disciplines could work together to create unique solutions for patients' problems." In designing interventional suites of the future, two of the new endovascular suites have glass walls and a video system that allow people to sit in a theater-style chair outside of the suite and control what they are watching using an iPad. Viewers from different disciplines or in training each can have their own unique user interface that allows them to pick and choose which parts of the procedure they want to watch, all with communication with the suites. Additionally, the Institute makeover created the National Center for Aneurysm Therapy -- the first in the world -- a Center for Structural Heart Therapy, Center for Critical Limb Ischemia and an Advanced Arrhythmia Therapy Center. It is here where physicians are doing research to discover more cardiovascular disease breakthroughs. "We are proud to open the doors of the new Miami Cardiac & Vascular Institute to our community," said Brian E. Keeley, President and CEO of Baptist Health South Florida. "This expansion now provides even greater promise to our patients, with new state-of-the-art interventional procedure suites; an expansive, high-tech gallery for observation, diagnostics and greater teaching opportunities; and, research space for more than 120 clinical trials." Miami Cardiac & Vascular Institute is the largest and most comprehensive cardiovascular facility in the region, consisting of 76 doctors and 1,100 employees system-wide serving 125,000 patients every year. "At Philips, we are committed to building a healthy society by creating solutions that are going to have a meaningful impact in improving human health, and this requires collaboration with pioneering organizations like Miami Cardiac & Vascular Institute," said Brent Shafer, CEO of Philips North America. "The Institute's clinical insights have been critical to the development of our Azurion technology, from understanding workflows and improving efficiencies, to understand how to improve the patient experience. Together, we are shaping the future of healthcare by making procedures safer and more efficient. This will not only help address the health issues in South Florida communities, it will allow us to apply those lessons globally to help tackle the challenges of rising healthcare costs and better access to care. Ultimately, we want to improve the patient experience and outcomes, one community at a time." Miami Cardiac & Vascular Institute is the largest and most comprehensive cardiovascular facility in the region. The team of multilingual, multidisciplinary specialists has pioneered the development of minimally invasive techniques used to treat aneurysms, blockages in veins and arteries and holes in the heart. Miami Cardiac & Vascular Institute is part of Baptist Health South Florida, the largest healthcare organization in the region, with seven hospitals (Baptist Hospital, Baptist Children's Hospital, Doctors Hospital, Homestead Hospital, Mariners Hospital, South Miami Hospital and West Kendall Baptist Hospital), nearly 50 outpatient and urgent care facilities, Baptist Health Medical Group, Baptist Health Quality Network and internationally renowned centers of excellence. The not-for-profit, faith-based Baptist Health has approximately 16,000 employees and 2,300 affiliated physicians. Baptist Health South Florida has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World's Most Ethical Companies. For more information, visit BaptistHealth.net and connect with us on Facebook at facebook.com/BaptistHealthSF and on Twitter and Instagram @BaptistHealthSF. Royal Philips (NYSE: PHG) (AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.


MELVILLE, N.Y., Nov. 28, 2016 /PRNewswire/ -- Virtual Imaging, a wholly owned subsidiary of Canon U.S.A., Inc., a leader in digital imaging, is proud to announce that Baptist Health South Florida, the largest healthcare organization in the region1, has purchased the RadPRO®2 OMNERA® 400T...


News Article | November 14, 2016
Site: www.eurekalert.org

From 2002 to 2013, the use of statins increased substantially among U.S. adults, although use in high-risk groups remains suboptimal, and there are persistent disparities among women, racial/ethnic minorities, and the uninsured, according to a study published online by JAMA Cardiology. The study is being released to coincide with its presentation at the American Heart Association's Scientific Sessions 2016. Statins are one of the most well-established measures for the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). Guidelines released by the American Heart Association and the American College of Cardiology broadened the proportion of U.S. adults in whom statins are indicated from 37.5 percent (43.2 million) to 48.6 percent (56 million). These guidelines also included specific recommendations about using high-intensity statins among select high-risk individuals. However, contemporary data on national patterns for statin use are limited. Khurram Nasir, M.D., M.P.H., of Baptist Health South Florida, Miami, and colleagues examined trends in use and total and out-of-pocket (OOP) expenditures associated with statins in a representative U.S. adult population. Demographic, medical condition, and prescribed medicine information of adults 40 years and older between 2002 and 2013 were obtained from the Medical Expenditure Panel Survey database. From 2002 to 2013, more than 157,000 Medical Expenditure Panel Survey participants were eligible for the study (average age, 58 years; 52 percent female). Overall, statin use among U.S. adults 40 years of age and older in the general population increased 80 percent from 21.8 million individuals (18 percent) in 2002-2003 (134 million prescriptions) to 39.2 million individuals (28 percent) in 2012-2013 (221 million prescriptions). Among those with established ASCVD, statin use was 50 percent and 58 percent in 2002-2003 and 2012-2013, respectively, and less than one-third were prescribed as a high-intensity dose. Across all subgroups, statin use was significantly lower in women, racial/ethnic minorities, and the uninsured. The proportion of generic statin use increased substantially, from 8.4 percent in 2002-2003 to 82 percent in 2012-2013. Gross domestic product-adjusted total cost for statins decreased from $17.2 billion (OOP cost, $7.6 billion) in 2002-2003 to $16.9 billion (OOP cost, $3.9 billion) in 2012-2013, and the average annual OOP costs for patients decreased from $348 to $94. Brand-name statins were used by 18 percent of statin users, accounting for 55 percent of total costs in 2012-2013. "While total and OOP expenditures associated with statins decreased, further substitution of brand-name to generic statins may yield more savings," the authors write. "These findings have important public health implications and should stimulate further discussions among stakeholders for pragmatic patient-centered interventions to improve appropriate statin use and manage associated costs." Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.


BURLINGTON, Mass.--(BUSINESS WIRE)--Nuance Communications announced that Baptist Health South Florida has realized $45 million in increased appropriate reimbursement and improved quality of records since implementing Nuance CDI.


AMSTERDAM--(BUSINESS WIRE)--Royal Philips (NYSE:PHG, AEX:PHIA), a leader in health technology, today announced the global launch of Azurion, its next generation image-guided therapy platform, which forms the new core of its integrated solutions portfolio for the fast growing image-guided therapy market. As a leader in this market, Philips offers integrated solutions comprising interventional imaging technologies and planning and navigation software combined with interventional devices - including catheters for diagnosis and therapy - and a broad range of services, all aimed at helping clinicians to provide superior care at predictable costs. Following the acquisition of Volcano in 2015, via which Philips has become a leader in advanced catheters for diagnosis and therapy, the company is now further cementing its overall leadership in the EUR 5 billion image-guided therapy market with one of its largest global product launches in recent years. Philips’ Azurion image-guided therapy platform for interventional labs is the result of a multi-year development program conducted in close collaboration with leading clinicians in the field. This next generation platform features a state-of-the-art ergonomic design with an easy-to-use intuitive user interface, enabling clinicians to swiftly and confidently perform a wide range of routine and complex procedures in the interventional lab. With the rapid growth of image-guided therapy procedures, hospitals and health systems are increasingly faced with the need to control costs, while improving their standards of care. Azurion has been designed to address these challenges and is equipped with new workflow options and performance dashboards, as well as an upcoming range of productivity improvement services. The Azurion platform also features over 1,000 new components, including an enhanced flat-panel detector, and Philips’ newly developed ConnectOS operating system for the seamless integration of real-time information from all relevant technologies in the interventional lab. All of these components work together to deliver high image quality at ultra-low X-ray dose and real-time image processing on multiple work spots within the interventional lab. Parallel working enables the team of clinicians to complete different tasks simultaneously in the interventional lab, saving valuable time without compromising quality of care. Azurion features procedure cards that allow clinicians to pre-program routine tasks and user preferences, helping to minimize preparation errors and further reducing preparation and procedure time. Philips has pioneered a steady stream of innovations in planning and navigation software for areas such as vascular surgery (e.g. VesselNavigator), interventional cardiology (e.g. EchoNavigator), interventional oncology (e.g. EmboGuide), and interventional neuroradiology (e.g. AneurysmFlow). All these advanced interventional tools integrate seamlessly into the Azurion platform to support the clinical workflow. Driven by their benefits for patients and care providers, minimally-invasive therapies, such as the catheter-based treatment of certain tumors, aneurysms, obstructed blood vessels, heart rhythm disorders and defective heart valves, continue to grow fast. In addition to reduced patient trauma and shorter recovery times, such procedures also have the benefit of allowing the treatment of patients who would not be able to withstand the trauma of open surgery. However, during such procedures, clinicians cannot directly see and feel the organs they are working on. Effective imaging, measurement and navigation technologies are therefore key to guiding minimally-invasive procedures. At the heart of the interventional lab, these technologies allow identification and visualization of target organs and tissues, the operation of interventional devices, and the placement of implants, leading to improved chances of therapy success. “For over 30 years, we’ve pioneered minimally-invasive treatments that help our patients get back to their daily lives,” said Barry T. Katzen, MD, founder and Chief Medical Executive of the Miami Cardiac & Vascular Institute, Baptist Health South Florida (U.S.). “The imaging environment is critical to perform such procedures efficiently and effectively. As an interventionalist, we want to be in the cockpit, similar to a pilot in an airplane, where we have control of everything we need and have all the relevant functions at our finger tips. Philips’ next generation image-guided therapy platform just takes it to a whole other level and allows interventionalists to accomplish the procedures quicker and more efficiently, which benefits the patient." “As a leader in image-guided therapy, we have been driving continuous innovation to address rising patient volumes and increased procedure complexity,” said Bert van Meurs, Business Leader Image Guided Therapy at Philips. “Hundreds of Philips developers, engineers and designers and dozens of our clinical partners across the world have collaborated to completely redesign the heart of our portfolio. With the launch of our new Azurion platform, which was designed to optimize system integration and lab performance, we can deliver new turnkey solutions that support our customers in maintaining high standards of quality and patient care at predictable costs.” “We are on an exciting journey to strengthen the Tampere Heart Hospital’s position as a Northern European center of excellence for cardiac care,” said Aki Haukilahti, Executive Vice President and CFO of Heart Hospital, Tampere University Hospital (Finland). “As part of our long-term strategic partnership with Philips, we have collaborated on a turnkey solution based on the new Azurion product family. With this solution, Philips provides us with advanced technologies and an excellent user experience, combined with services for guaranteed uptime, seamless integration into our hospital workflows, staff training and education, and enhancement of our productivity. This enables our staff to fully focus on what they do best – providing superior care to our patients.” Click on this link or type www.philips.com/azurion in your internet browser to visit the Philips Azurion website. Royal Philips (NYSE:PHG, AEX:PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips’ health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.


Royal Philips (NYSE: PHG, AEX: PHIA), a leader in health technology, today announced the global launch of Azurion, its next generation image-guided therapy platform, which forms the new core of its integrated solutions portfolio for the fast growing image-guided therapy market. As a leader in this market, Philips offers integrated solutions comprising interventional imaging technologies and planning and navigation software combined with interventional devices - including catheters for diagnosis and therapy - and a broad range of services, all aimed at helping clinicians to provide superior care at predictable costs. Following the acquisition of Volcano in 2015, via which Philips has become a leader in advanced catheters for diagnosis and therapy, the company is now further cementing its overall leadership in the EUR 5 billion image-guided therapy market with one of its largest global product launches in recent years. Philips' Azurion image-guided therapy platform for interventional labs is the result of a multi-year development program conducted in close collaboration with leading clinicians in the field. This next generation platform features a state-of-the-art ergonomic design with an easy-to-use intuitive user interface, enabling clinicians to swiftly and confidently perform a wide range of routine and complex procedures in the interventional lab. With the rapid growth of image-guided therapy procedures, hospitals and health systems are increasingly faced with the need to control costs, while improving their standards of care. Azurion has been designed to address these challenges and is equipped with new workflow options and performance dashboards, as well as an upcoming range of productivity improvement services. Azurion is Philips' next generation image-guided therapy platform and the new core of its integrated solutions portfolio. Azurion supports a full range of configurations across a broad spectrum of image-guided therapy procedures. These include configurations for high volume routine procedures and flexible configurations for advanced procedures. Harnessing vital procedural information from various sources, such as imaging systems, interventional devices, navigation tools and patient health records, Azurion provides interventional staff members with the control and information they need to perform procedures efficiently. The Azurion platform also features over 1,000 new components, including an enhanced flat-panel detector, and Philips' newly developed ConnectOS operating system for the seamless integration of real-time information from all relevant technologies in the interventional lab. All of these components work together to deliver high image quality at ultra-low X-ray dose and real-time image processing on multiple work spots within the interventional lab. Parallel working enables the team of clinicians to complete different tasks simultaneously in the interventional lab, saving valuable time without compromising quality of care. Azurion features procedure cards that allow clinicians to pre-program routine tasks and user preferences, helping to minimize preparation errors and further reducing preparation and procedure time. Philips has pioneered a steady stream of innovations in planning and navigation software for areas such as vascular surgery (e.g. VesselNavigator), interventional cardiology (e.g. EchoNavigator), interventional oncology (e.g. EmboGuide), and interventional neuroradiology (e.g. AneurysmFlow). All these advanced interventional tools integrate seamlessly into the Azurion platform to support the clinical workflow. Driven by their benefits for patients and care providers, minimally-invasive therapies, such as the catheter-based treatment of certain tumors, aneurysms, obstructed blood vessels, heart rhythm disorders and defective heart valves, continue to grow fast. In addition to reduced patient trauma and shorter recovery times, such procedures also have the benefit of allowing the treatment of patients who would not be able to withstand the trauma of open surgery. However, during such procedures, clinicians cannot directly see and feel the organs they are working on. Effective imaging, measurement and navigation technologies are therefore key to guiding minimally-invasive procedures. At the heart of the interventional lab, these technologies allow identification and visualization of target organs and tissues, the operation of interventional devices, and the placement of implants, leading to improved chances of therapy success. "For over 30 years, we've pioneered minimally-invasive treatments that help our patients get back to their daily lives," said Barry T. Katzen, MD, founder and Chief Medical Executive of the Miami Cardiac & Vascular Institute, Baptist Health South Florida (U.S.). "The imaging environment is critical to perform such procedures efficiently and effectively. As an interventionalist, we want to be in the cockpit, similar to a pilot in an airplane, where we have control of everything we need and have all the relevant functions at our finger tips. Philips' next generation image-guided therapy platform just takes it to a whole other level and allows interventionalists to accomplish the procedures quicker and more efficiently, which benefits the patient." "As a leader in image-guided therapy, we have been driving continuous innovation to address rising patient volumes and increased procedure complexity," said Bert van Meurs, Business Leader Image Guided Therapy at Philips. "Hundreds of Philips developers, engineers and designers and dozens of our clinical partners across the world have collaborated to completely redesign the heart of our portfolio. With the launch of our new Azurion platform, which was designed to optimize system integration and lab performance, we can deliver new turnkey solutions that support our customers in maintaining high standards of quality and patient care at predictable costs." "We are on an exciting journey to strengthen the Tampere Heart Hospital's position as a Northern European center of excellence for cardiac care," said Aki Haukilahti, Executive Vice President and CFO of Heart Hospital, Tampere University Hospital (Finland). "As part of our long-term strategic partnership with Philips, we have collaborated on a turnkey solution based on the new Azurion product family. With this solution, Philips provides us with advanced technologies and an excellent user experience, combined with services for guaranteed uptime, seamless integration into our hospital workflows, staff training and education, and enhancement of our productivity. This enables our staff to fully focus on what they do best - providing superior care to our patients." Click on this link or type http://www.philips.com/azurion in your internet browser to visit the Philips Azurion website. Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries. News about Philips can be found at http://www.philips.com/newscenter.

Loading Baptist Health South Florida collaborators
Loading Baptist Health South Florida collaborators